Medical Device Company - Preparing FDA 510K Application for Market Introduction. Urology and more specifically Benign Prostatic Hyperplasia (BPH) is a large market opportunity effecting over 500 Million Men globally. BPH surgical technology has not seen any significant advancements in how urologists treat patients suffering from BPH. UroTech Inc. was established to create innovative technologies that will enable urologists to quickly and easily treat BPH surgically while eliminating and or significantly reducing the negative side effects associated with older surgical techniques.
| Website | http://www.urotechsurgical.com |
| Revenue | $1 million |
| Employees | 1 (1 on RocketReach) |
| Industry | Medical Devices, Drug Manufacturing & Research, Pharmaceuticals, Healthcare |
| Web Rank | 26 Million |
| Keywords | Bph Treatment, Benign Prostatic Hyperplasia, Urology Technology, Prostate Surgery, Surgical Technology, Prostate Health, Urological Instruments, Prostate Treatment, Minimally Invasive Surgery, Surgical Instruments, Medical Technology, Men's Health, Market Introduction, Medical Innovation, Healthcare Technology |
| Competitors | Medtronic, Stryker, Boston Scientific, Zimmer Biomet, Smith+Nephew, Cook Medical, Teleflex, Coloplast, CR Bard - Europe, Middle East and Africa (EMEA), Ethicon, Inc. +40 more (view full list) |
| SIC | SIC Code 38 Companies, SIC Code 384 Companies |
| NAICS | NAICS Code 33 Companies, NAICS Code 334 Companies |
Looking for a particular UroTech Surgical employee's phone or email?
UroTech Surgical Questions
The UroTech Surgical annual revenue was $1 million in 2026.
Thomas Hunter is the Director of UroTech Surgical.
1 people are employed at UroTech Surgical.
The NAICS codes for UroTech Surgical are [33, 334].
The SIC codes for UroTech Surgical are [38, 384].
Top UroTech Surgical Employees
-
Thomas Hunter
Director at UroTech Surgical
Medford, MA, US1
Related Companies
